Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia
Top Cited Papers
Open Access
- 28 September 2017
- Vol. 67 (12), 2131-2141
- https://doi.org/10.1136/gutjnl-2016-313586
Abstract
Objective DNA-based testing of pancreatic cyst fluid (PCF) is a useful adjunct to the evaluation of pancreatic cysts (PCs). Mutations in KRAS/GNAS are highly specific for intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), while TP53/PIK3CA/PTEN alterations are associated with advanced neoplasia. A prospective study was performed to evaluate preoperative PCF DNA testing. Design Over 43-months, 626 PCF specimens from 595 patients were obtained by endoscopic ultrasound (EUS)-fine needle aspiration and assessed by targeted next-generation sequencing (NGS). Molecular results were correlated with EUS findings, ancillary studies and follow-up. A separate cohort of 159 PCF specimens was also evaluated for KRAS/GNAS mutations by Sanger sequencing. Results KRAS/GNAS mutations were identified in 308 (49%) PCs, while alterations in TP53/PIK3CA/PTEN were present in 35 (6%) cases. Based on 102 (17%) patients with surgical follow-up, KRAS/GNAS mutations were detected in 56 (100%) IPMNs and 3 (30%) MCNs, and associated with 89% sensitivity and 100% specificity for a mucinous PC. In comparison, KRAS/GNAS mutations by Sanger sequencing had a 65% sensitivity and 100% specificity. By NGS, the combination of KRAS/GNAS mutations and alterations in TP53/PIK3CA/PTEN had an 89% sensitivity and 100% specificity for advanced neoplasia. Ductal dilatation, a mural nodule and malignant cytopathology had lower sensitivities (42%, 32% and 32%, respectively) and specificities (74%, 94% and 98%, respectively). Conclusions In contrast to Sanger sequencing, preoperative NGS of PCF for KRAS/GNAS mutations is highly sensitive for IPMNs and specific for mucinous PCs. In addition, the combination of TP53/PIK3CA/PTEN alterations is a useful preoperative marker for advanced neoplasia.Keywords
Funding Information
- Pancreatic Cancer Action Network
This publication has 32 references indexed in Scilit:
- Molecular Diagnostics in the Evaluation of Pancreatic CystsSurgical Pathology Clinics, 2016
- A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic CystsGastroenterology, 2015
- Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the PancreasClinical Gastroenterology and Hepatology, 2015
- Systematic Review of Pancreatic Cyst Fluid Biomarkers: The Path ForwardClinical and Translational Gastroenterology, 2015
- Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing DataThe Journal of Molecular Diagnostics, 2014
- PreoperativeGNASandKRASTesting in the Diagnosis of Pancreatic Mucinous CystsClinical Cancer Research, 2014
- Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst DevelopmentScience Translational Medicine, 2011
- Cystic precursors to invasive pancreatic cancerNature Reviews Gastroenterology & Hepatology, 2011
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations: Diagnostic and Clinical ImplicationsThe Journal of Molecular Diagnostics, 2010
- Precursors to Pancreatic CancerGastroenterology Clinics of North America, 2007